Low hepatic cytochrome P450 3A activity is a risk for corticosteroid- induced osteonecrosis [1]

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 4, 2007, Pages 379-

  Nafziger, A N ^a   Bertino Jr , J S ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CORTICOSTEROID; CYTOCHROME P450 3A; ERYTHROMYCIN; LIVER ENZYME; MIDAZOLAM;

ACCURACY; AREA UNDER THE CURVE; BONE NECROSIS; BREATH ANALYSIS; CORRELATION ANALYSIS; DRUG CLEARANCE; ENZYME ACTIVITY; FEMUR; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; MEDICAL RESEARCH; PRIORITY JOURNAL; RISK;

ADRENAL CORTEX HORMONES; BIOLOGICAL MARKERS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; FEMUR HEAD NECROSIS; HUMANS; HYDROXYLATION; LIVER; MIDAZOLAM; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SUBSTRATE SPECIFICITY;

EID: 34548664602     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100105     Document Type: Letter

References (8)

1. Kaneshiro, Y. et al. Low hepatic cytochrome P450 3A activity is a risk for corticosteroid-induced osteonecrosis. Clin. Pharmacol. Ther. 80, 396-402 (2006).
2. Kim, J.S. et al. Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. J. Clin. Pharmacol. 42, 376-382 (2002).
3. Lee, L.S., Bertino, J.S. Jr & Nafziger, A.N. Limited sampling models for oral midazolam:midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity. J. Clin. Pharmacol. 46, 229-234 (2006).
4. Thummel, K.E. et al. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J. Pharmacol. Exp. Ther. 271, 557-566 (1994).
5. Rogers, J.F. et al. Single plasma concentrations of 1′-hydroxymidazolam or the ratio of 1′-hydroxymidazolam:midazolam do not predictmidazolamclearance in healthy subjects. J. Clin. Pharmacol. 42, 1079-1082 (2002).
6. Lin, Y.S. et al. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 11, 781-791 (2001).
7. Bjornsson, T.D. et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. 31, 815-832 (2003).
8. Food and Drug Administration. Drug interaction studies - study design, data analysis, and implications for dosing and labeling. In Guidance for Industry (ed. Pharmacology C.) US Department of Health and Human Services, Food and Drug Administration, Rockville, 2006, pp 1-34.